SCHEMBL397800

SCHEMBL397800

Nc1ncnc2c1ncn2[C@@H]1O[C@H](C(O)Cl)[C@@H](O)[C@H]1O

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHCY P23526 12/20 0.68
PRMT5 O14744 1/20 0.68
WDR77 Q9BQA1 1/20 0.68
ADORA2A P29274 2/20 0.67
ADORA2B P29275 2/20 0.67
DPP4 P27487 1/20 0.67
MEN1 O00255 1/20 0.67
SLC28A1 O00337 1/20 0.67
MAP3K7 O43318 1/20 0.67
SLC28A2 O43868 1/20 0.67
GAPDH P04406 1/20 0.67
ADORA3 P0DMS8 1/20 0.67
MAPK1 P28482 1/20 0.67
ADORA1 P30542 1/20 0.67
STAT6 P42226 1/20 0.67
PI4KA P42356 1/20 0.67
KMT2A Q03164 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
PI4K2B Q8TCG2 1/20 0.67
DOT1L Q8TEK3 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31680251 1.00 AHCY (0.68) AHCYPRMT5WDR77ADORA2AADORA2B
SCHEMBL9874701 0.95 AHCY (0.65) AHCYPRMT5WDR77ADORA2AADORA2B
SCHEMBL9874712 0.95 AHCY (0.65) AHCYPRMT5WDR77ADORA2AADORA2B
SCHEMBL7803295 0.94 AHCY (0.67) AHCYPRMT5WDR77ADORA2AADORA2B
SCHEMBL6671788 0.94 AHCY (0.67) AHCYPRMT5WDR77ADORA2AADORA2B
SCHEMBL25390909 0.92 AHCY (0.66) AHCYPRMT5WDR77ADORA2AADORA2B
SCHEMBL2040666 0.92 PRMT5 (0.66) AHCYPRMT5WDR77ADORA2AADORA2B
SCHEMBL25390247 0.92 AHCY (0.66) AHCYPRMT5WDR77ADORA2AADORA2B
SCHEMBL4650654 0.92 AHCY (0.66) AHCYPRMT5WDR77ADORA2AADORA2B
SCHEMBL8990546 0.92 AHCY (0.66) AHCYPRMT5WDR77ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1483279-A1 PROCESSES FOR THE SYNTHESIS OF 5'-DEOXY-5'-CHLOROADENOSINE AND 5'-DEOXY-5'-METHYLTHIOADENOSINE PFIZER INC. (US) 2004-12-08 EP claimed
US-20030181713-A1 Processes for the synthesis of chloroadenosine and methylthioadenosine SRIRANGAM JAYARAM KASTURI (US) 2003-09-25 US claimed
WO-2003074541-A1 PROCESSES FOR THE SYNTHESIS OF 5’-DEOXY-5’ CHLOROADENOSINE AND 5’-DEOXY-5’METHYLTHIOADENOSINE PFIZER INC. (US) 2003-09-12 WO claimed
US-20020177695-A1 Nucleic acid probes and methods DUKE UNIVERSITY 2002-11-28 US claimed
US-6288221-B1 REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES DUKE UNIVERSITY 2001-09-11 US claimed
JP-5255378-A None JP disclosed
JP-61171423-A None JP disclosed
US-12516080-B2 Remdesivir and remdesivir analogs, solutions, and nanoparticle, liposomal, and microparticle compositions for treating viral infections THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2026-01-06 US disclosed
US-12103955-B2 Polynucleotides encoding relaxin MODERNATX, INC. (US) 2024-10-01 US disclosed
US-20230183282-A1 REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2023-06-15 US disclosed
WO-2021202907-A2 REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-10-07 WO disclosed
US-11091509-B2 HPPK inhibitors useful as antibacterial agents THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2021-08-17 US disclosed
EP-0390112-A2 Selective adenosine receptor agents MERRELL PHARMACEUTICALS INC. (US) 1990-10-03 EP disclosed
EP-0390111-A2 Selective adenosine receptor compounds MERRELL DOW PHARMACEUTICALS INC. (US) 1990-10-03 EP disclosed
EP-0269574-A2 Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1988-06-01 EP disclosed
EP-0253962-A2 Use of adenosine derivatives as anti-dementia agents HOECHST JAPAN LIMITED (JP) 1988-01-27 EP disclosed
JP-S61171423-A DRUG FOR ALLEVIATING DENTAL CARIES AND PERIODONTOSIS ADVANCE RES & DEV CO LTD 1986-08-02 JP disclosed
US-4560795-A α-Halomethyl derivatives of α-amino acids Merrell Dow France et Cie. (FR) 1985-12-24 US disclosed
US-4438270-A DECARBOXYLASE INHIBITORS MERRELL TORAUDE ET COMPAGNIE (FR) 1984-03-20 US disclosed
US-4376116-A TREATMENT OF CYSTIC FIBROSIS AND PARASITIC INFECTIONS RESEARCH CORPORATION (US) 1983-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12103955-B2 Polynucleotides encoding relaxin RXFP1, RXFP2, RXFP4 AHCY 4159/4885PRMT5 516/4885WDR77 1769/4885
US-11091509-B2 HPPK inhibitors useful as antibacterial agents PDXK, PHKG1, DTYMK AHCY 213/4885PRMT5 1952/4885WDR77 1094/4885
US-20020177695-A1 Nucleic acid probes and methods NUDT1, NT5C3B, NT5C2 AHCY 228/4885PRMT5 3119/4885WDR77 2751/4885
US-20030181713-A1 Processes for the synthesis of chloroadenosine and methylthioadenosine MTAP, ADAR, NUDT1 AHCY 35/4885PRMT5 1146/4885WDR77 340/4885
US-20230183282-A1 REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONS ALB, ACE, ACE2 AHCY 1849/4885PRMT5 660/4885WDR77 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.